HPLC method for determination of related substances of cabazitaxel

By using octadecylsilane bonded silica gel chromatography column and gradient elution method in HPLC method, the problem of difficulty in separating cabatassa and its degraded substances was solved, efficient and accurate quality control was achieved, and the cabatassa was met and its impurities detection requirements.

CN110133168BActive Publication Date: 2024-11-08SICHUAN KELUN PHARMA RES INST CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN201910077437.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-02-09
Filing Date
2019-01-25
Publication Date
2024-11-08
Estimated Expiration
2039-01-25

AI Technical Summary

Technical Problem

The existing HPLC method is difficult to accurately detect cabatastridium and its degraded substances and isomer impurities, which makes it difficult to control cabatastridium quality and cannot effectively separate and determine the content of these impurities.

Method used

Using octadecylsilane-bonded silica gel chromatography column, the gradient elution method of aqueous phase-acetonitrile-methanol was used to adjust the volume ratio and gradient elution conditions of the mobile phase, and combine the acidic water regulated by phosphoric acid as the mobile phase to optimize the detection wavelength. and temperature to achieve effective separation of cabataxel and its degraded substances.

Benefits of technology

It realizes efficient separation of cabatassium and its degraded substances, with accurate detection results, high sensitivity, simple operation, low cost, good precision and repeatability, and the impurity recovery rate is between 90 and 110%.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110133168B_ABST
    Figure CN110133168B_ABST
Patent Text Reader

Abstract

The invention discloses a method for determining cabazitaxel related substances by HPLC, wherein an octadecylsilane bonded silica gel chromatographic column is selected, and a water phase-acetonitrile-methanol is used as a mobile phase for gradient elution to determine the cabazitaxel related substances, wherein the mobile phase consists of a mobile phase A and a mobile phase B, wherein the volume ratio of acetonitrile-methanol-water phase in the mobile phase A is 40-50:5-15:40-50, and the volume ratio of acetonitrile-methanol-water phase in the mobile phase B is 60-70:5-15:25. The invention adopts HPLC to determine the cabazitaxel related substances, can effectively separate cabazitaxel and its degradation substances, and has good separation degree and high sensitivity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug analysis, and relates to a method for determining cabazitaxel-related substances by HPLC, in particular to a method for determining cabazitaxel isomers or process impurities. Background Art

[0002] Cabazitaxel, chemical name is (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tert-butyloxycarbonyl)amino]-2-hydroxy-3-phenylpropionyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytaxanthin-11-en-2-yl benzoate, molecular formula is C 45 H 57 NO 14 , the chemical structure is as follows:

[0003]

[0004] During the stability study of cabazitaxel API and preparation, it was found that it is sensitive to ultraviolet light and high temperature, and quality control is required for degradation impurities in API and preparation. Since isomer impurities are similar to the main component in structure and polarity, it is difficult to separate them in liquid phase and establish methods. Currently, there is no report on an effective method for accurately and sensitively detecting the content of cabazitaxel isomer impurities.

[0005] The impurities of Cabazitaxel mainly come from the following three sources: first, the starting materials and intermediates introduced during the synthesis of the raw materials of this product; second, the by-products generated during the raw material synthesis reaction; third, the degradation impurities generated by the product during the reaction process and storage due to environmental influences. These impurities will affect the purity and quality of the drug, and it is necessary to establish analytical methods for related substances to control the content of these impurities.

[0006] CN 103217493 B discloses a method for determining cabazitaxel-related substances by using HPLC, which uses C18 chromatography to detect starting materials, intermediate by-products in the synthesis of cabazitaxel, but does not provide a method for detecting cabazitaxel and its degradation products and isomers.

[0007] The document "Screening of methods for testing cabazitaxel-related substances" (Li Mingyue, "Biotechnology World", Issue 4, 2016, pp. 186-188) discloses two detection methods. Method 1 uses mobile phase A: acetonitrile, mobile phase B: sodium dihydrogen sulfate aqueous solution, and phosphoric acid to adjust the pH to 3.5; Method 2 uses mobile phase A: ammonium sulfate buffer-methanol (1708:292, w / w), mobile phase B: sulfuric acid buffer-methanol (758:242, w / w) to perform gradient elution to detect cabazitaxel and its degradation substances. Combining the method screening and the structural information of cabazitaxel and impurities, it can be seen that this detection method cannot ensure that cabazitaxel and its impurities are completely eluted. The review test was started according to the method in the document, and the results showed that cabazitaxel and the degradation products could not be separated and failed to elute. Summary of the invention

[0008] The object of the present invention is to provide a method for determining cabazitaxel-related substances by HPLC, which can be used for the determination of cabazitaxel and its degradation substances.

[0009] In order to achieve the above-mentioned purpose, the technical solution of the present invention is as follows:

[0010] A method for determining cabazitaxel-related substances by HPLC, wherein an octadecylsilane bonded silica gel chromatographic column is selected, and a water phase-acetonitrile-methanol mobile phase is used for gradient elution to determine the cabazitaxel-related substances. Preferably, the mobile phase consists of a mobile phase A and a mobile phase B, wherein the volume ratio of acetonitrile-methanol-water phase in the mobile phase A is 40-50:5-15:40-50, and the volume ratio of acetonitrile-methanol-water phase in the mobile phase B is 60-70:5-15:25.

[0011] Preferably, the volume ratio of acetonitrile-methanol-water in the mobile phase A is 42-45:8-15:42-48, and the volume ratio of acetonitrile-methanol-water in the mobile phase B is 62-68:8-15:25; more preferably, the volume ratio of acetonitrile-methanol-water in the mobile phase A is 45:10:45, and the volume ratio of acetonitrile-methanol-water in the mobile phase B is 65:10:25.

[0012] A further technical solution is that the gradient elution conditions are as follows:

[0013] 0min, the volume fractions of mobile phase A and mobile phase B were 100% to 95% and 0% to 5%, respectively;

[0014] 7min, the volume fractions of mobile phase A and mobile phase B were 67% to 57% and 33% to 43%, respectively;

[0015] 40min-50min, the volume fractions of mobile phase A and mobile phase B are 27%-17% and 73%-83% respectively;

[0016] 50.1min~60min, the volume fractions of mobile phase A and mobile phase B are 100%~95% and 0%~5% respectively.

[0017] Preferably, the aqueous phase is acidic water adjusted with phosphoric acid, and has a pH of 3.5 to 6.0, preferably, a pH of 4.0 to 4.5, and more preferably, a pH of 4.0.

[0018] A further technical solution is that the filler particle size of the octadecylsilane bonded silica gel chromatographic column is 3 to 5 μm.

[0019] A further technical solution is that the detection wavelength is 210-280 nm, preferably, the detection wavelength is 230 nm.

[0020] A further technical solution is that the detection temperature is 25-30°C, preferably, the column temperature is 30°C.

[0021] A further technical solution is that the flow rate of the mobile phase is 0.5-2.0 ml / min, and the injection volume of the sample is 5 μl-20 μl; preferably, the flow rate of the mobile phase is 1.0 ml / min, and the injection volume of the sample is 20 μl.

[0022] A further technical solution is that the gradient elution conditions are as follows:

[0023] 0min, the volume fractions of mobile phase A and mobile phase B were 100% to 95% and 0% to 5%, respectively;

[0024] 7min, the volume fractions of mobile phase A and mobile phase B were 67%-62% and 33%-38%, respectively;

[0025] 40min-50min, the volume fractions of mobile phase A and mobile phase B are 27%-22% and 73%-78% respectively;

[0026] 50.1min~60min, the volume fractions of mobile phase A and mobile phase B are 100%~95% and 0%~5% respectively.

[0027] A further technical solution is that the gradient elution conditions are as follows:

[0028] 0min, the volume fractions of mobile phase A and mobile phase B were 100% and 0%, respectively;

[0029] 7min, the volume fractions of mobile phase A and mobile phase B were 65%-62% and 35%-38%, respectively;

[0030] 40min-50min, the volume fractions of mobile phase A and mobile phase B are 25%-22% and 75%-78% respectively;

[0031] From 50.1min to 60min, the volume fractions of mobile phase A and mobile phase B are 100% and 0%, respectively.

[0032] According to a specific technical solution, the volume fractions of mobile phase A and mobile phase B during gradient elution are as follows:

[0033] 0min, 100%, 0%;

[0034] 7min, 62%, 38%;

[0035] 40min~50min, 22%, 78%;

[0036] 50.1min~60min, 100%, 0%.

[0037] According to a specific technical solution, the volume fractions of mobile phase A and mobile phase B during gradient elution are as follows:

[0038] 0min, 100%, 0%;

[0039] 7min, 67%, 33%;

[0040] 40min~50min, 27%, 73%;

[0041] 50.1min~60min, 100%, 0%.

[0042] According to a specific technical solution, the volume fractions of mobile phase A and mobile phase B during gradient elution are as follows:

[0043] 0min, 95%, 5%;

[0044] 7min, 57%, 43%;

[0045] 40min~50min, 17%, 83%;

[0046] 50.1min~60min, 95%, 5%.

[0047] A further technical solution is that the method comprises the following steps:

[0048] Step A: Preparation of test solution: Take an appropriate amount of cabazitaxel or a preparation containing cabazitaxel, add 75% acetonitrile to dilute it to prepare a solution containing 1 mg of cabazitaxel per 1 ml, which is used as the test solution;

[0049] Step B: Preparation of control solution: Accurately measure 1 ml of the test solution prepared in step A above, place it in a 100 ml volumetric flask, add 75% acetonitrile to dilute to the mark, shake well, and use it as the control solution;

[0050] Step C: Determination method: Accurately measure 10μl~20μl of the control solution and inject it into the liquid chromatograph, adjust the detector sensitivity, then accurately measure the test solution in an amount equal to the control solution and inject it into the liquid chromatograph, and record the chromatogram.

[0051] Compared with the prior art, the present invention has the following beneficial effects:

[0052] The present invention adopts HPLC method to determine the related substances of cabazitaxel, can effectively separate cabazitaxel and its degradation substances, have no mutual interference, good separation degree and high sensitivity, and is simple to operate, easy to control, low in detection cost, and has good precision, stability, sensitivity and repeatability, the impurity accuracy recovery rate is 90-110%, and the detection result is accurate and reliable. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 This is the HPLC chromatogram of Cabazitaxel and its related substances in Example 1;

[0054] Figure 2 is the HPLC chromatogram of Cabazitaxel and its related substances in Example 2;

[0055] Figure 3 is the HPLC chromatogram of Cabazitaxel and its related substances in Example 3;

[0056] Figure 4 This is the HPLC chromatogram of Cabazitaxel after high temperature degradation in Example 4;

[0057] Figure 5 HPLC chromatogram of Cabazitaxel and its related substances in Comparative Example 1;

[0058] Figure 6 The HPLC chromatogram of Cabazitaxel and its related substances in Comparative Example 2;

[0059] Figure 7 The HPLC chromatogram of Cabazitaxel and its related substances in Comparative Example 3. DETAILED DESCRIPTION

[0060] In order to better understand the technical solution of the present invention, the technical solution of the present invention is further described below in conjunction with the specific implementation modes of the present invention, but the present invention is not limited thereto.

[0061] In the present invention, the term "cabazitaxel" can refer to pure products, raw materials, synthetic products, etc. of cabazitaxel, without distinction, and the determination methods of the present invention are applicable to the quality control of the above products, and the determination methods of the related substances of these products are also protected within the scope of protection of the present invention.

[0062] In the present invention, the term "related substances" refers to impurities that may be produced during the preparation and storage of drugs. In the embodiment of the present invention, the related substances of cabazitaxel include impurity E, impurity F and impurity I, and their structural formulas are as follows:

[0063] Impurity E:

[0064] Impurity F:

[0065] Impurity E and impurity F are commercially available, for example, provided by Shenzhen Xianggen Biotechnology Co., Ltd.

[0066] The preparation method of impurity I is as follows:

[0067] Take the cabazitaxel raw material and an appropriate amount of anhydrous ethanol (API-anhydrous ethanol 5g: 200ml, or appropriately increase the API concentration), place it in an 80°C water bath for reflux extraction for 11 days. The ethanol reflux solution is concentrated under reduced pressure to about 20-50ml (sample concentration is about 0.1g / ml), and the preparative liquid phase separation and purification is performed, and the preparative solution is freeze-dried to obtain impurity I. The chromatographic conditions for preparative liquid phase separation and purification are as follows:

[0068] Chromatographic column: Waters Sunfire Prep C18 OBD 19mm×250mm×5μm

[0069] Flow rate: 1.0 ml / min; Run time: 36 min; Injection volume: 550 μl; Detection wavelength: 215 nm; Column temperature: room temperature

[0070] Mobile phase: Mobile phase A: acetonitrile-methanol-water in a volume ratio of 45:10:45; Mobile phase B: acetonitrile-methanol-water in a volume ratio of 65:10:25.

[0071] The conditions for gradient elution were as follows:

[0072] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 100 0 7 62 38 30 35 65 32 35 65 33 100 0 36 100 0

[0073] Embodiment 1:

[0074] 1. Instruments and conditions

[0075] Instrument: Agilent 1200 liquid chromatograph; DAD detector; chromatographic column: Shiseido C18, 4.6 mm × 250 mm, 5 μm; detection wavelength: 230 nm; column temperature: 30°C; flow rate: 1 ml / min.

[0076] Mobile phase A: acetonitrile-methanol-acidic water (water was adjusted to pH 4.0 with phosphoric acid), volume ratio of 45:10:45;

[0077] Mobile phase B: acetonitrile-methanol-acidic water (water was adjusted to pH 4.0 with phosphoric acid), volume ratio of 65:10:25.

[0078] Linear gradient elution was performed according to the following Table 1; wherein % is the volume fraction of mobile phase A or mobile phase B in the mobile phase.

[0079] Table 1: Elution conditions of Example 1

[0080] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 100 0 7 62 38 40 22 78 50 22 78 50.1 100 0 60 100 0

[0081] 2. Test steps

[0082] Accurately weigh 3 mg of the samples of cabazitaxel photodegradation impurities E, F, and I into a 5 ml volumetric bottle, add an appropriate amount of DMF to dissolve, then add 75% acetonitrile to dilute to the scale, shake well, and use as the impurity reference stock solution;

[0083] Take appropriate amount of Cabazitaxel reference substance and impurity reference substance stock solution, add acetonitrile to dilute and prepare a mixed solution containing 1 mg of Cabazitaxel and 5 μg of Cabazitaxel photodegradation impurities E, F and I per 1 ml, as the system suitability solution, take 20 μl and inject into the liquid chromatograph, record the chromatogram, and the results are shown in the table. Figure 1 The retention time and separation degree of each substance are shown in Table 2.

[0084] Table 2: Retention time and separation degree of HPLC detection in Example 1

[0085] Serial number Retention time Separation 1 7.299 - 2 12.868 18.96 3 17.266 11.53 4 18.597 2.96 5 19.613 2.14 6 21.007 2.82 7 22.230 2.34 8 36.826 22.97 9 41.320 5.85 10 42.915 1.99

[0086] The results showed that under this chromatographic condition, the chromatographic peak with a retention time of about 2 minutes in the system suitability solution was the DMF solvent peak, the elution time of cabazitaxel was 18.597 minutes, the elution time of impurity E was 19.613 minutes, the elution time of impurity I was 21.007 minutes, and the elution time of impurity F was 22.230 minutes. The separation degrees between cabazitaxel and impurities and between impurities were all greater than 2.0, which met the system suitability requirements.

[0087] Embodiment 2:

[0088] 1. Instruments and conditions

[0089] Instrument: Agilent 1200 liquid chromatograph; DAD detector; chromatographic column: Shiseido C18, 4.6 mm × 250 mm, 5 μm; detection wavelength: 230 nm; column temperature 30 °C;

[0090] Mobile phase A: acetonitrile-methanol-acidic water (water was adjusted to pH 4.0 with phosphoric acid), volume ratio of 45:10:45;

[0091] Mobile phase B: acetonitrile-methanol-acidic water (water was adjusted to pH 4.0 with phosphoric acid), volume ratio of 65:10:25.

[0092] Linear gradient elution was performed according to Table 3 below; wherein % is the volume fraction of mobile phase A or mobile phase B in the mobile phase.

[0093] Table 3: Elution conditions of Example 2

[0094] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 100 0 7 67 33 40 27 73 50 27 73 50.1 100 0 60 100 0

[0095] 2. Test steps

[0096] Accurately weigh 3 mg of the samples of cabazitaxel photodegradation impurities E, F, and I into a 5 ml volumetric bottle, add an appropriate amount of DMF to dissolve, then add 75% acetonitrile to dilute to the scale, shake well, and use as the impurity reference stock solution;

[0097] Take appropriate amount of Cabazitaxel reference substance and impurity reference substance stock solution, add acetonitrile to dilute and prepare a mixed solution containing 1 mg of Cabazitaxel and 5 μg of Cabazitaxel photodegradation impurities E, F and I per 1 ml, as the system suitability solution, take 20 μl and inject into the liquid chromatograph, record the chromatogram, and the results are shown in the table. Figure 2 The retention time and separation degree of each substance are shown in Table 4.

[0098] Table 4: Retention time and separation degree of HPLC detection in Example 2

[0099] Serial number Retention time Separation 1 7.389 - 2 13.217 19.75 3 18.082 12.08 4 19.482 2.81 5 20.102 2.12 6 22.102 2.86 7 23.412 2.35 8 38.625 22.53 9 43.177 5.65 10 44.928 2.05

[0100] The results showed that under this chromatographic condition, the chromatographic peak with a retention time of about 2 minutes in the system suitability solution was the DMF solvent peak, the elution time of cabazitaxel was 19.482 minutes, the elution time of impurity E was 20.598 minutes, the elution time of impurity I was 22.102 minutes, and the elution time of impurity F was 23.412 minutes. The separation between cabazitaxel and impurities and between impurities was greater than 2.0, which met the system suitability requirements.

[0101] Embodiment 3:

[0102] 1. Instruments and conditions

[0103] Instrument: Agilent 1200 liquid chromatograph; DAD detector; chromatographic column: Shiseido C18, 4.6 mm × 250 mm, 5 μm; detection wavelength: 230 nm; column temperature 30 °C;

[0104] Mobile phase A: acetonitrile-methanol-acidic water (water was adjusted to pH 4.0 with phosphoric acid), volume ratio of 45:10:45;

[0105] Mobile phase B: acetonitrile-methanol-acidic water (water was adjusted to pH 4.0 with phosphoric acid), volume ratio of 65:10:25.

[0106] Linear gradient elution was performed according to Table 5 below; wherein % is the volume fraction of mobile phase A or mobile phase B in the mobile phase.

[0107] Table 5: Elution conditions of Example 3

[0108] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 95 5 7 57 43 40 17 83 50 17 83 50.1 95 5 60 95 5

[0109] 2. Test steps

[0110] Accurately weigh 3 mg of the samples of cabazitaxel photodegradation impurities E, F, and I into a 5 ml volumetric bottle, add an appropriate amount of DMF to dissolve, then add 75% acetonitrile to dissolve and dilute to the scale, shake well, and use as the impurity reference stock solution;

[0111] Take appropriate amount of Cabazitaxel reference substance and impurity reference substance stock solution, add acetonitrile to dilute and prepare a mixed solution containing 1 mg of Cabazitaxel and 5 μg of Cabazitaxel photodegradation impurities E, F and I per 1 ml, as the system suitability solution, take 20 μl and inject into the liquid chromatograph, record the chromatogram, and the results are shown in the table. Figure 3 The retention time and separation degree of each substance are shown in Table 6.

[0112] Table 6: Retention time and separation degree of HPLC detection in Example 3

[0113] Serial number Retention time Separation 1 7.035 - 2 12.177 18.78 3 16.067 10.93 4 17.203 2.56 5 18.123 1.94 6 19.372 2.66 7 20.507 2.16 8 33.764 21.14 9 37.853 5.61 10 39.374 1.96

[0114] The results showed that under this chromatographic condition, the chromatographic peak with a retention time of about 2 minutes in the system suitability solution was the DMF solvent peak, the elution time of cabazitaxel was 17.203 minutes, the elution time of impurity E was 18.123 minutes, the elution time of impurity I was 19.372 minutes, and the elution time of impurity F was 20.507 minutes. The separation between cabazitaxel and impurities and between impurities was greater than 1.94, which met the system suitability requirements.

[0115] Linearity and Range:

[0116] Accurately weigh an appropriate amount of each impurity, add 75% acetonitrile to dissolve and dilute to a solution with a concentration of 5μg / ml as the impurity stock solution. Accurately measure an appropriate amount of the stock solution and add a diluent to prepare a series of linear solutions (the concentration range is from the quantitative limit concentration to about 5μg / ml). Conduct linearity tests on each of the above solutions. Linear regression analysis was performed with concentration (C) as the abscissa (X-axis) and peak area (A) as the ordinate (Y-axis) to calculate the respective linear regression equations and correlation coefficients r. The correlation coefficients r of the impurities were all greater than 99.9%. Impurity E was linear in the range of 0.2223 μg / ml to 4.9402 μg / ml (relative to the test sample concentration of 0.022% to 0.494%), impurity I was linear in the range of 0.2167 μg / ml to 4.8153 μg / ml (relative to the test sample concentration of 0.022% to 0.482%), and impurity F was linear in the range of 0.2195 μg / ml to 4.8770 μg / ml (relative to the test sample concentration of 0.022% to 0.488%).

[0117] Limit of Quantitation and Limit of Detection

[0118] Take impurities E, I and F, add 75% acetonitrile to make a solution with a concentration of 0.2mg / ml, then add 75% acetonitrile to dilute to the appropriate concentration, accurately measure 20μl of the above solution and inject it into the liquid chromatograph, record the chromatogram, take 10 times the signal-to-noise ratio as the quantitative limit, and 3 times the signal-to-noise ratio as the detection limit. The results show that the quantitative limit concentration of impurities E, I, and F is equivalent to 0.022% of the main component, and the detection limit concentration is equivalent to 0.007% of the main component. The method has high sensitivity.

[0119] Repeatability

[0120] Weigh about 25 mg of cabazitaxel bulk drug sample, accurately weigh, place in a 25 ml volumetric flask, add 75% acetonitrile to dissolve and dilute to the scale, shake well, as the test solution, accurately measure 1 ml of the test solution, place in a 100 ml volumetric flask, add 75% acetonitrile to dilute to the scale, shake well, as the control solution, prepare 6 portions in parallel, and test according to Example 1. Impurity E and impurity I were not detected. The test results are shown in Table 7:

[0121] Table 7: Test results of repeatability experiment

[0122]

[0123] Intermediate precision

[0124] According to the repeatability test, 6 samples were prepared in parallel at different times and by different experimenters, and the test was carried out on different instruments according to Example 1. Impurity E and impurity I were not detected. The test results are shown in Table 8:

[0125] Table 8: Test results of intermediate precision experiment

[0126]

[0127] Impurity recovery experiment

[0128] According to the impurity E limit of 0.15%, and the impurity F and I limits of 0.1%, three levels of recovery tests at 50%, 100% and 150% of the limit concentration were designed to verify the accuracy of the method, as follows.

[0129] Impurity stock solution: Accurately weigh appropriate amounts of impurities E, F, and I, respectively, dissolve and dilute in 75% acetonitrile to make solutions with concentrations of approximately 15 μg / ml for impurity E and 25 μg / ml for impurities F and I.

[0130] Impurity reference solution: Accurately measure impurity E and place it in a 10ml volumetric flask. Place 1ml of impurity F and I stock solutions in a 25ml volumetric flask. Add 75% acetonitrile to dissolve and dilute to the scale. Shake well to obtain.

[0131] Test solution: Accurately weigh 25 mg of cabazitaxel, place in a 25 ml volumetric flask, add 75% acetonitrile to dissolve and dilute to the scale, sonicate, shake well, and obtain.

[0132] Impurity E recovery rate sample: Weigh about 10 mg of cabazitaxel, accurately weigh, place in a 10 ml volumetric flask, add 0.5 ml, 1.0 ml, 1.5 ml of impurity stock solution respectively, add 75% acetonitrile to dissolve and dilute to the scale, sonicate, shake well, and prepare three samples in parallel for each recovery rate concentration.

[0133] 50% impurity F and I recovery rate sample: Weigh about 25 mg of cabazitaxel accurately, place in a 25 ml volumetric flask, add 0.5 ml of impurity stock solution, add 75% acetonitrile to dissolve and dilute to scale, sonicate, shake well, and prepare three samples in parallel.

[0134] 100% impurity F and I recovery rate sample: Weigh about 25 mg of cabazitaxel accurately, place in a 25 ml volumetric flask, add 1.0 ml of impurity stock solution, add 75% acetonitrile to dissolve and dilute to scale, sonicate, shake well, and prepare three samples in parallel.

[0135] 150% impurity F and I recovery rate sample: Weigh about 25 mg of cabazitaxel accurately, place in a 25 ml volumetric flask, add 1.5 ml of impurity stock solution, add 75% acetonitrile to dissolve and dilute to scale, sonicate, shake well, and prepare three samples in parallel.

[0136] The above solution was accurately measured and tested according to Example 1. The results showed that the recovery rate of each impurity ranged from 90.0% to 110.0%, and the method had good accuracy. The data are summarized in Tables 9-11:

[0137] Table 9: Impurity E-recovery test results

[0138]

[0139]

[0140] Table 10: Impurity F-recovery test results

[0141]

[0142] Table 11: Impurity I-Recovery Test Results

[0143]

[0144] Example 4: Detection of related substances after the test sample was placed at high temperature

[0145] 1. Instruments and conditions

[0146] Instrument: Agilent 1200 liquid chromatograph; DAD detector; chromatographic column: Shiseido C18, 4.6 mm × 250 mm, 5 μm; detection wavelength: 230 nm; column temperature 30 °C;

[0147] Mobile phase A: acetonitrile-methanol-acidic water (water was adjusted to pH 4.0 with phosphoric acid), volume ratio of 45:10:45;

[0148] Mobile phase B: acetonitrile-methanol-acidic water (water was adjusted to pH 4.0 with phosphoric acid), volume ratio of 65:10:25.

[0149] Linear gradient elution was performed according to the following Table 12; wherein % is the volume fraction of mobile phase A or mobile phase B in the mobile phase.

[0150] Table 12: Elution conditions of Example 4

[0151] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 100 0 7 62 38 40 22 78 50 22 78 50.1 100 0 60 100 0

[0152] 2. Test steps

[0153] Take an appropriate amount of the sample of Cabazitaxel injection after it has been placed at 60°C for 30 days, weigh it accurately, add 75% acetonitrile to dissolve it and dilute it to make a solution containing 1 mg of Cabazitaxel per 1 ml, which is used as the test solution;

[0154] Accurately measure 1 ml of the test solution, place it in a 100 ml volumetric flask, add 75% acetonitrile to dilute to the mark, shake well, and use it as the control solution. Accurately measure 20 μl of the test solution and the control solution, respectively, inject them into the liquid chromatograph, and record the chromatogram. If there is a degradation impurity peak in the test solution, its peak area shall not be greater than the main peak area of ​​the control solution (0.5%). See the results. Figure 4 .

[0155] The results showed that under this chromatographic condition, the chromatographic peak with a retention time of about 2 minutes in the system suitability solution was the DMF solvent peak, the elution time of cabazitaxel was 18.113 minutes, the elution time of impurity I was 20.403 minutes, the elution time of impurity F was 22.099 minutes, and the impurity E did not elute. The maximum single impurity I content in the sample was 0.79%, and the total impurity content was 1.38%. The related substances of cabazitaxel met the limit requirements and can be used for the detection and control of related substances in cabazitaxel raw materials and preparations.

[0156] Comparative Example 1:

[0157] 1. Instruments and conditions

[0158] Instrument: Agilent 1200 liquid chromatograph; DAD detector; chromatographic column: Shiseido C18, 4.6 mm × 250 mm, 5 μm; detection wavelength: 230 nm; column temperature 35 °C;

[0159] Perform linear gradient elution according to Table 13 below;

[0160] Table 13: Elution conditions of Comparative Example 1

[0161] Time (minutes) Acetonitrile (%) water(%) 0 60 40 30 85 15 50 100 0 55 85 15 60 60 40

[0162] 2. Test steps

[0163] Take 20 μl of the system suitability solution in Example 1 and inject it into the liquid chromatograph to record the chromatogram. The results are shown in Figure 5 .

[0164] The results showed that under this chromatographic condition, the retention time of the main peak was 11.761 minutes, and it did not achieve baseline separation with the adjacent impurities. The chromatographic peak with a retention time of 22.915 minutes was actually the superposition of two process impurities and could not be separated under this method.

[0165] Comparative Example 2:

[0166] 1. Instruments and conditions

[0167] Instrument: Agilent 1200 liquid chromatograph;

[0168] Mobile phase A: acetonitrile;

[0169] Mobile phase B: 0.067 mol / L sodium dihydrogen phosphate aqueous solution, with phosphoric acid adjusting the pH to 3.5.

[0170] Chromatographic column: Shimadzu C18, 4.6mm×250mm, 5μm. Detection wavelength: 210nm. Column temperature: 30℃. Flow rate: 1.0ml / min

[0171] Table 14: Elution conditions of Comparative Example 2

[0172] Time (minutes) Mobile phase A (%) Mobile phase B (%) 0 8 92 4 8 92 18 15 85 30 20 80 30.1 8 92 40 8 92

[0173] 2. Test steps

[0174] Take 20 μl of the system suitability solution in Example 1 and inject it into the liquid chromatograph to record the chromatogram. The results are shown in Figure 6 .

[0175] The results showed that under this chromatographic condition, the 4-5 minute chromatographic peak in the system suitability solution was a superposition of the DMF solvent peak and some impurities, while cabazitaxel and more impurities did not elute, making it impossible to determine the related substances.

[0176] Comparative Example 3:

[0177] 1. Instruments and conditions

[0178] Instrument: Agilent 1200 liquid chromatograph;

[0179] Mobile phase A: ammonium sulfate buffer (take 1.32 g of ammonium sulfate, add 2000 ml of water, add 0.4 ml of sulfuric acid)-methanol (1708:292, w / w);

[0180] Mobile phase B: ammonium sulfate buffer-methanol (758:242, w / w).

[0181] Chromatographic column: Waters Symmetry C18 5μm 150×3.0mm.

[0182] Detection wavelength: 210nm. Column temperature: 30℃. Flow rate: 0.6ml / min.

[0183] Table 15: Elution conditions of Comparative Example 3

[0184]

[0185]

[0186] 2. Test steps

[0187] Take 20 μl of the system suitability solution in Example 1 and inject it into the liquid chromatograph to record the chromatogram. The results are shown in Figure 7 .

[0188] The results showed that under this chromatographic condition, there was only a solvent peak in the system suitability solution, the chromatographic peaks of each substance did not reach baseline separation, and cabazitaxel and its impurities did not elute.

Claims

1. A method for determining related substances of cabazitaxel by HPLC, characterized in that: An octadecylsilane bonded silica gel chromatographic column was selected, and a water phase-acetonitrile-methanol mobile phase was used for gradient elution to determine the cabazitaxel-related substances. The mobile phase consisted of a mobile phase A and a mobile phase B. The volume ratio of acetonitrile-methanol-water phase in the mobile phase A was 40-50:5-15:40-50, and the volume ratio of acetonitrile-methanol-water phase in the mobile phase B was 60-70:5-15:

25. The gradient elution conditions are as follows: 0min, the volume fractions of mobile phase A and mobile phase B were 100% to 95% and 0% to 5%, respectively; 7min, the volume fractions of mobile phase A and mobile phase B were 67% to 57% and 33% to 43%, respectively; 40min-50min, the volume fractions of mobile phase A and mobile phase B are 27%-17% and 73%-83% respectively; 50.1min~60min, the volume fractions of mobile phase A and mobile phase B are 100%~95% and 0%~5% respectively.

2. The method for determining the related substances of cabazitaxel by HPLC according to claim 1, characterized in that The volume ratio of acetonitrile-methanol-water phase in the mobile phase A is 42-45:8-15:42-48, and the volume ratio of acetonitrile-methanol-water phase in the mobile phase B is 62-68:8-15:

25.

3. The method for determining the related substances of cabazitaxel by HPLC according to claim 1, characterized in that The volume ratio of acetonitrile-methanol-water in the mobile phase A is 45:10:45, and the volume ratio of acetonitrile-methanol-water in the mobile phase B is 65:10:

25.

4. The method for determining the related substances of cabazitaxel by HPLC according to claim 1, characterized in that The aqueous phase is acidic water adjusted with phosphoric acid, and its pH value is 3.5-6.

0.

5. The method for determining the related substances of cabazitaxel by HPLC according to claim 4, characterized in that The pH of the aqueous phase is 4.0-4.

5.

6. The method for determining the related substances of cabazitaxel by HPLC according to claim 5, characterized in that The pH of the aqueous phase is 4.

0.

7. The method for determining the related substances of cabazitaxel by HPLC according to claim 1, characterized in that The filler particle size of the octadecylsilane bonded silica gel chromatographic column is 3-5 μm.

8. The method for determining the related substances of cabazitaxel by HPLC according to claim 1, characterized in that The detection wavelength is 210~280nm.

9. The method for determining the related substances of cabazitaxel by HPLC according to claim 8, characterized in that The detection wavelength is 230 nm.

10. The method for determining the related substances of cabazitaxel by HPLC according to claim 1, characterized in that The detection temperature is 25-30℃.

11. The method for determining the related substances of cabazitaxel by HPLC according to claim 10, characterized in that The detection temperature is 30°C.

12. The method for determining the related substances of cabazitaxel by HPLC according to claim 1, characterized in that The gradient elution conditions are as follows: At 0 min, the volume fractions of mobile phase A and mobile phase B were 100% to 95% and 0% to 5% respectively; at 7 min, the volume fractions of mobile phase A and mobile phase B were 67% to 62% and 33% to 38% respectively; at 40 min to 50 min, the volume fractions of mobile phase A and mobile phase B were 27% to 22% and 73% to 78% respectively; 50.1min~60min, the volume fractions of mobile phase A and mobile phase B are 100%~95% and 0%~5% respectively.

13. The method for determining the related substances of cabazitaxel by HPLC according to claim 1, characterized in that The gradient elution conditions are as follows: 0min, the volume fractions of mobile phase A and mobile phase B were 100% and 0%, respectively; 7min, the volume fractions of mobile phase A and mobile phase B are 65%-62% and 35%-38% respectively; 40min-50min, the volume fractions of mobile phase A and mobile phase B are 25%-22% and 75%-78% respectively; From 50.1min to 60min, the volume fractions of mobile phase A and mobile phase B are 100% and 0%, respectively.

14. The method for determining the related substances of cabazitaxel by HPLC according to claim 1, characterized in that The gradient elution conditions are as follows: 0min, the volume fractions of mobile phase A and mobile phase B were 100% and 0%, respectively; 7min, the volume fractions of mobile phase A and mobile phase B were 62% and 38%, respectively; 40min-50min, the volume fractions of mobile phase A and mobile phase B were 22% and 78% respectively; 50.1min~60min, the volume fractions of mobile phase A and mobile phase B are 100% and 0% respectively; or, 0min, the volume fractions of mobile phase A and mobile phase B are 100% and 0% respectively; 7min, the volume fractions of mobile phase A and mobile phase B were 67% and 33%, respectively; 40min-50min, the volume fractions of mobile phase A and mobile phase B were 27% and 73% respectively; 50.1min~60min, the volume fractions of mobile phase A and mobile phase B are 100% and 0% respectively; or, 0min, the volume fractions of mobile phase A and mobile phase B are 95% and 5% respectively; 7min, the volume fractions of mobile phase A and mobile phase B were 57% and 43%, respectively; 40min-50min, the volume fractions of mobile phase A and mobile phase B were 17% and 83% respectively; From 50.1min to 60min, the volume fractions of mobile phase A and mobile phase B are 95% and 5% respectively.

Citation Information

Patent Citations

  • Method for measuring cabazitaxel related substances by using HPLC (High Performance Liquid Chromatography) method

    CN103217493B

  • Method for preparing cabazitaxel by taking 10-deacetylate-baccatin III as raw material

    CN102417491A

  • Synthesis method of cabazitaxel

    CN102532065A

  • Amorphous cabazitaxel and preparation method thereof

    CN102659722A

  • Method for purifying cabazitaxel

    CN102887877A